<DOC>
	<DOC>NCT00310505</DOC>
	<brief_summary>This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.</brief_summary>
	<brief_title>Amphotericin B Treatment in Visceral Leishmaniasis</brief_title>
	<detailed_description>This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Parasitologically proved kalaazar HIV positive serology</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>visceral leishmaniasis</keyword>
	<keyword>amphotericin B</keyword>
	<keyword>Kala-azar</keyword>
</DOC>